AI companies run virtual drug trials, aim to improve success of human studies

AI Funding & IPOs (Google News)October 7, 2026en

AI Funding & IPOs (Google News)

AI Global Wire

Novartis’ experimental del-desiran for a rare type of muscular dystrophy was expected to be a winner, with the Swiss company's CEO predicting annual peak sales of $5 billion. When a late-stage trial ...

This is a short summary published by AI Global Wire. The full article is owned and hosted by AI Funding & IPOs (Google News) — open it there to read it in full.